Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Ontology highlight
ABSTRACT: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Patients are titrated to an effective-dose of fentanyl sublingual spray in the open-label titration period and then proceed to the double-blind randomized period where they randomly receive 7 treatments with fentanyl sublingual spray and 3 treatments with placebo. Patients are treated for up to a total of 6-7 weeks (including both the open-label titration and the double-blind randomized periods).
DISEASE(S): Extramedullary Plasmacytoma,Primary Myelofibrosis,Pain,Cancer Pain,Angioimmunoblastic T-cell Lymphoma,Monoclonal Gammopathy Of Undetermined Significance,Cancer
PROVIDER: 2044922 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA